Clinical Trial Update: Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II [Phase 2]

View source ↗

Summary

This document reports the completion of a randomized Phase II trial comparing peptide receptor radionuclide therapy with Lutetium-177 dotatate versus Sunitinib …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Neuroendocrine Tumor

Drugs mentioned

• LUTATHERA (Lutetium Lu-177 dotatate)
• Sutent (sunitinib)

Snippet

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Conditions: Pancreatic Neuroendocrine Carcinoma | Phase 2 | Status: COMPLETED